Human Journals

Case Report

September 2017 Vol.:10, Issue:2

© All rights are reserved by AYESHA HABEEB et al.

Budd Chairi Syndrome- A Case Report and Review of Literature



AYESHA HABEEB*1

*1Deccan school of pharmacy, *1Department of pharmacy Practice, Dar us salam, Aghapura, Nampally, Hyderabad, Telangana, India.

Submission: 19 August 2017
Accepted: 27 August 2017
Published: 30 September 2017



www.ijppr.humanjournals.com

Keywords: Budd Chiari syndrome (BCS), Hepatic Encephalopathy, Alcoholic Liver Disease, Fatty Liver, Acute Gastroenteritis.

ABSTRACT

"Budd Chiari syndrome (BCS)" is an uncommon condition induced by thrombotic or nonthrombotic obstruction to hepatic venous outflow. This disease can be potentially life-threatening but prognosis is more favorable in patient with Inferior Vena Ceva webs but is extremely poor in malignant and haematological cases. A cooperative collaboration of hepatologist and cardiologist can make the situation easy for diagnosis, even in the treatment of some cases. The literature available on management of Budd Chairi Syndrome is scarce. In this Case report, the author present a case of 49 years old male patient who was admitted in Gastroenterology department of a tertiary care hospital with chief complaints of: Nausea, Vomiting, Pain in abdomen, Blood in the stool, Fever, Abdominal distension, Shortness of breath, Pedal oedema and from the final diagnosis the patient was diagnosed with Budd Chairi Syndrome, Hepatic Encephalopathy, Alcoholic Liver Disease & Fatty Liver Associated with Acute Gastroenteritis. The patient presented with acute deterioration in liver function and diffuse pain in abdomen and ascites. The liver enzymes stabilized on conservative management. There was feature of encephalopathy and bleeding tendency during hospital stay. However, ascites increased and became more tense and painful with prominent dilated veins over chest and abdomen. The Case report has been presented providing the detailed information of the Case in SOAP format. The author reviews the literature and discusses treatment options available for the management.

INTRODUCTION:

Budd-Chiari syndrome (BCS) was originally described as a rare vascular disorder that encompasses an array of symptoms due to obstruction of hepatic blood outflow at the level of the hepatic veins or hepatic portion of the inferior vena cava (IVC)¹. The symptoms resulting from this type of occlusion of the hepatic outflow, "classical BCS", was first described by Budd^{2,3} in 1845 and later by Hans Chiari in 1899. With the advancement of diagnostic and therapeutic techniques, providers have expanded upon these initial characterizations⁴. Historically, identifying the precise location of the obstruction was challenging, leading to the propagation of simplified descriptions. The precise location of the obstruction(s) is however clinically and prognostically significant. As Valla⁵ proposed, the clinical manifestations of BCS (the selective group of symptoms that characterize the syndrome) can be explained by the location of the obstruction: Within the hepatic veins vs within the IVC at the level of the hepatic ostia. Over time, in order to incorporate novel and more detailed findings associated with BCS, the lexicon has evolved discordantly. The lexicon now includes a myriad of ambiguous terms or eponyms: Budd's disease, Chiari's disease, Chiari's syndrome, Rokitansky's disease, von Rokitansky disease, Hepatic vein outflow tract obstruction, membranous obstruction of the IVC, obliterative hepatocavopathy, Hepatic vena cava disease, Budd-Chiari syndrome with occlusion of hepatic vein, or hepatic vein thrombosis^{6,8}. These eponyms have been used at some point during the course of further discovery; this disarray of terms, some of which are unclear and nonspecific, reflects not only the heterogeneous presentation of BCS, but also the possibility of distinct entities within this syndrome.

The currently accepted definition of primary BCS is hepatic outflow obstruction regardless of the cause or level of obstruction^{6, 9}. The obstruction can range from the small hepatic veins to the orifice of the IVC into the right atrium. Sinusoidal obstruction syndrome is excluded from this definition^{6, 9}. Secondary BCS is defined as a hepatic venous outflow obstruction due to compression or invasion by extravascular lesions, including benign or malignant diseases such as abscesses, hepatocellular carcinomas, and renal cell carcinomas, or secondary to cardiac or pericardial diseases^{6, 9}.

In 1998, Okuda et al⁴ proposed that primary hepatic venous thrombosis (classical BCS) and thrombosis of the IVC at the level of the IVC were two separate syndromes. Recent studies continue to suggest a clear division within the definition of "primary BCS" based on the location of the obstructive lesion^{4,10}. Obstruction of the hepatic veins or "classical BCS"

appears to be more common in Western patient populations and usually has a known etiology¹¹, acute onset of symptoms, and a greater severity of symptoms requiring a different therapeutic approach than obstruction of the IVC at the level of the hepatic veins^{13, 14}. In comparison with "classical BCS", hepatic vena cava (HVC)-BCS appears to be more common in East Asian patient population and is more often idiopathic or due to membranous obstruction. HVC-BCS more commonly presents with a chronic onset of less severe symptoms, thus requiring a different therapeutic approach than "classical BCS". The location, size, and chronicity are clinically important as it dictates the patient's symptoms and directs the therapeutic approach for patient management¹⁰.

ETIOLOGY OF BUDD CHAIRI SYNDROME:

CAUSES	DISEASE
	Pregnancy
	Pills
Thrombosis	Myeloproliferative disorder
	Paroxysmal nocturnal Hemoglobinuria
W.	Polycythemia rubra vera
Non Thrombotic	Compression or invasion of IVC
Non Imonibotic	Membranous obstruction/IVC diaphragm
Systemic	Behcet syndrome
Systemic	Inflammatory Bowel Disease

PATHOGENESIS OF BUDD CHAIRI SYNDROME:

Blockage of two or more major hepatic veins increases the sinusoidal pressure and reduces sinusoidal blood flow. Obstruction of a single hepatic vein is generally not evident; two veins must be blocked for clinical disease¹⁶. The result of these hemodynamic changes is sinusoidal dilation and filtration of interstitial fluid. Filtrated interstitial fluid passes through the liver capsule when it exceeds the capacity of lymphatic drainage. Thus, liver congestion, right upper quadrant pain and ascites occur.

Portal pressure increases and perfusion of the liver *via* portal vein is decreased. The combined effect of these changes in hepatic circulation on liver parenchyma is hypoxic damage of hepatocytes. Non-inflammatory centrilobular cell necrosis is found in nearly 70% of cases. Reperfusion injury may contribute to hepatocyte damage. Hepatocyte necrosis coordinates

with release of free oxygen radicals and inflammation. Massive hepatocellular damage with a fulminant course is rare. Usually, portal hypertension and ascites are seen in chronic form. Both the acute and chronic forms result in severe centrilobular congestion and hepatocellular necrosis and atrophy. Within a few weeks after obstruction, fibrosis develops predominantly in the centrilobular are Within a few months, nodular regeneration may be seen predominantly in the periportal area. Progressive fibrosis, nodular regenerative hyperplasia and cirrhosis develop during the course of disease. Interventional portosystemic shunts or development of portal venous collateral system may improve liver functions and delay the cirrhotic process ^{15,19}.

The caudate lobe, which has direct venous drainage into the IVC, often undergoes compensatory hypertrophy. Caudate lobe hypertrophy is found in half of the cases and causes IVC stenosis. Obstruction of the portal vein is present in 10%-20% of cases and may be related to stagnant blood flow and underlying thrombophilic disorder^{17,18}.




Figure 1: Budd Chairi Syndrome

REVIEW OF LITERATURE:

S.NO	AUTHOR	TITLE	CONCLUSION
			A treatment strategy is
			recommended where
			anticoagulation is given
			first, followed by
	Aure liePlessier,		angioplasty when
1.	Dominique-Charles,	Budd-Chiari	appropriate, then TIPS in
1.	Valla, et al	Syndrome	patients not responding to
	vana, et al		previous measure, and
			finally liver transplantation.
			This strategy has achieved
			5-year survival rates close
			to 90%.
			Several works have enabled
		A.	the comprehension of
		HUMAN	Budd-Chiari syndrome as
			well as the diagnosis and
			treatment. This clinical
			review attempted to present
			the Budd-Chiari syndrome
2.	A.V. Kyriakidis,	Budd-Chiari	overall and more
	Vezyrgiannis , M. Pyrgioti	syndrome	particularly the history,
			etiology, pathophysiology,
			diagnosis and the
			understanding of the latest
			developments in
			conservative and surgical
			management as well as
			prognosis.
	Praveen K Ro, BS	Budd-Chiari	The prognosis is poor in
3.	Anand, Sarah D	Syndrome	patients with Budd-Chiari
	Komanapalli,		syndrome who remain

Citation: AYESHA HABEEB et al. Ijppr.Human, 2017; Vol. 10 (2): 272-293.

4.	Naomi Shin, Young H Kim, Hao Xu, Hai-Bin Shi, Qing-Qiao Zhang, Jean Paul Colon Pons, Ducksoo Kim, Yi Xu, Fei-Yun Wu, Samuel Han, Byung-Boong Lee, and Lin-Sun Li	Redefining Budd-Chiari syndrome: A systematic review	portosystemic shunting, however, the 5-year survival rate for patients with the BC syndrome is 38-87%. The actuarial 5-year survival rate following liver transplantation is 70%. Systematic review of recent data suggests that classical BCS and HVC-BCS may be two clinically different disorders that involve the disruption of hepatic venous outflow.
5.	PieterMartens and Frederik Nevens	Budd-Chiari syndrome	For the Budd-Chiari patient presenting with fulminant hepatic failure, first-line treatment with OLT(orthotopic liver transplantation) seems reasonable. It is clear that for these reasons patients with BCS should be treated in a center able to perform OLT.

	T		D.C.C.
			BCS requires accurate,
			prompt diagnosis, and
			aggressive therapy.
			Treatment will vary
			depending on the clinical
6.	Hector Ferral, George	Budd-Chiari	presentation, cause, and
0.	Behrens, and Jorge Lopera	Syndrome.	anatomic location of the
			problem. Patients with BCS
			are probably best treated in
			tertiary care centers where
			liver transplantation is
			available
			Multidisciplinary approach
			to diagnosis and treatment
			is advantageous in patients
			with BCS. Medical therapy
	7	81 h	consists of treatment of
		Budd Chiari	underlying disease,
	John D. Horton, Francisco	syndrome:	anticoagulation and
7.	L. San Miguel and Jorge	illustrated review	symptom control. Emerging
	A. Ortiz	of current	technologies have offered
		management	new minimally invasive
			treatment modalities such
			as percutaneous
			catheter-directed
			thrombolysis, angioplasty,
			stenting and TIPS.
	Duckin E I		A 23-year-old woman
	Dustin E Loomes, MA	A costs Dec 11 City	presented to hospital with a
0	Albert Chang, , Douglas	Acute Budd-Chiari	two-week history of
8.	Webber, Charles H	syndrome	abdominal pain, nausea and
	Scudamore ,and Eric M		increasing abdominal
	Yoshida		pain. Chronic Budd-Chiari

			syndrome is managed with
			anticoagulation and
			treatment of the
			complications of liver
			failure. Rarely, liver
			transplantation may be
			necessary.
			Budd-Chiari syndrome is a
			congestive hepatopathy
		Budd-Chiari	caused by blockage of
		syndrome:	hepatic veins. The liver
	Musa Aydinli and Yusuf	Etiology,	biopsy may be helpful for
9.	Bayraktar	pathogenesis and	differential diagnosis. The
		diagnosis	prognosis of the chronic
			form is acceptable
			compared to other chronic
	,	8 h	liver diseases.
		HUMAN	Budd-Chiari syndrome
			(BCS) occurs when there is
			obstruction of the hepatic
			veins. Liver transplantation
	Cura M, Haskal Z, Lopera J; Boozari B, Bahr MJ, Kubicka S, et al	Budd-Chiari Syndrome	may be appropriate if there
			is decompensated liver
10.			cirrhosis.Reconstructing
			hepatic venous outflow
			post-transplant is
			sometimes a problem but
			successful venoplasty using
			autologous vein grafts has
			been reported.
	Vatsala Misra, Kachnar	The Budd-Chiari	This case report highlights a
11.	Verma, Dharmendra	Syndrome in a	rare case of BCS in a child.
	Kumar Singh, and Sri	Child: A Case	A high index of clinical
ĺ	1		

7.

	Prakash Misra	Report and Review	suspicion, along with a
		of the Literature	radiological aid and a
			histopathological
			correlation, can lead to an
			early diagnosis and an
			appropriate management in
			such cases.
			The history of a 20-year-old
			woman admitted for
			thrombosis of the hepatic
			veins and of the inferior
			vena cava (IVC) with
	Ouhadi L, Creemers	Budd-Chiari	extension of the thrombus
12.	E, Honoré P, Delwaide	syndrome: a case	into the right atrium.
12.	J, Marchetta S, Defraigne	report and review	Finally, Hepatic
	JO.	of the literature.	transplantation should be
	,	1 h	considered in case of
		HUMAN	treatment ineffectiveness,
			of fulminant hepatic failure,
			or of an evolution towards
			cirrhosis.
			Severe vascular
		Budd-Chiari	complications of
		syndrome in a	Budd-Chiari syndrome in
	Daniela T Carvalho,	25-year-old	patients with Behçet's
	Fernando T Oikawa,	woman with	disease are much more
13.	Nilce M Matsuda	Behçet's disease: a	common in young adult
Paulo RB Evora and	case report and	male patients; we present a	
	Alice T Yamada	review of the	rare case of Budd-Chiari
		literature	syndrome in a young
			Afro-Brazilian woman with
			Behçet's disease.
14.	Alok Khanna, Vijay	Acute Hepatitis	The patient presented with

	Lakshmi Sood , Dalal,	Like Presentation	progressively increasing
	Pankaj Abrol, Shalini	of Budd Chiari	ascites and pain abdomen
	Agarwal,	Syndrome in a	but without any bleeding
	1.28.11 11.11.1	Child	tendency, or
			encephalopathy. The initial
			diagnosis of acute hepatitis
			was proved wrong by
			contrast-enhanced CT scan
			of abdomen which showed
			atretic hepatic veins. Atretic
			hepatic veins causing Budd
			Chiari Syndrome (BCS) is a
			rarity in literature.
			A 23-year-old white woman
	Budd-Chiari Michael F. Sorrell Syndrome: Case Report		presented to doctor with a
			6-week history of
			progressive abdominal
			swelling. She received
15. Micha			furosemide to treat fluid
13.		retention. Two weeks later,	
			she returned to her
			physician with increasing
			abdominal discomfort and a
			5-kg weight gain. She was
			referred for specialty care
			A case of Budd-Chiari
		Budd-Chiari Syndrome Caused	syndrome that occurred in a
	A. S. Katkar, Anderson		transplanted cirrhotic liver
16.	H. Kuo, ¹ S. Calle, K.	by TIPS	from malpositioned
	Gangadhar, and K.	Malposition: A Case Report	proximal portion of the
	Chintapalli		TIPS in IVC causing
			occlusion of the ostia of
			hepatic veins which was

	T	T	aubaa anander dia a d
			subsequently diagnosed on
			contrast-enhanced CT. Ten
			days later, a follow-up CT
			of the abdomen and
			ultrasound was performed
			showing interval
			development of a fluid
			collection at the site of the
			previously documented
			liver hypoattenuation,
			consistent with hepatic
			abscess formation, was later
			drained via percutaneous
			approach using ultrasound
			guidance.
		,	Budd Chiari syndrome is a
	1		rare and confusing disease
	Md. Mukhlesur Rahman,	HUMAN	of the hepatic circulation.
	KMHS Sirajul Haque, Md.	'Budd Chiari	Sometimes it is
17.	Mahmudur Rahman	Syndrome' - A	misdiagnosed as a case of
	Siddiqui, Tanjima Parvin,	Case Report	only chronic liver disease
	Md. Khurshed Ahmed		but a good venography can
			remove all kind of
			confusion like this patient.
			In conclusion, this case
		Budd-Chiari	report highlights the
18.	Khaled Ali Jadallah,Enas		intriguing association
	Walid Sarsak, Yara	syndrome	between BCS and CD, and
	Mohammad Khazaleh,	associated with coeliac disease:	sheds some light on the
	Rawan Mohammad, Khair		putative pathogenic
	Barakat	case report and	mechanism. An underlying
		literature review	pro-thrombotic condition
			was detected in less than
L			

	T	T	I and the second
			50% of the patients,
			implying a possible
			thrombogenic role for CD.
			suggest that a diagnosis of
			CD should be pursued in
			the setting of BCS of
			undetermined cause.
			Similarly, CD patients with
			unexplained manifestations
			of acute or chronic liver
			injury should be assessed
			for BCS.
			The usefulness of these and
			additional criteria,
			however, needs to be
			established.With numbers
	Merz, Waltraut ,Rüland,	Pregnancy in	of women with BCS
	Anna, Hippe, Valeria	Budd-Chiari	seeking pregnancy
19.	,Poetzsch, Bernd, Meyer,	Syndrome: Case	expected to rise, the scoring
17.	Carsten, Pollok, Joerg M,	Report and	system may help in
	Gembruch, Ulrich	Proposed Risk	preconception risk
	Trebicka, Jonel	Score	assessment and counseling;
			furthermore, it may support
			in the establishment of
			treatment algorithms of
			BCS in pregnancy.
			Five patients responded to a
	David Clain. M.B,	Clinical diagnosis	modern diuretic regimen
	James Freston,	of the Budd-Chiari	and polycythaemia vera
20.	Louis Kreel.	syndrome: A	was successfully treated in
	Sheila Sherlock.	report of six cases	three. Exploratory surgery
	SHEHA SHEHUCK.	report of six cases	is not advised in the
			Budd-Chiari syndrome.
L	l	l	l

	Special roentgenologic
	procedures are the only
	means of making an
	accurate diagnosis.

CASE REPORT:

CASE REPORT ON BUDD CHAIRI SYNDROME, HEPATIC ENCEPHALOPATHY, ALCOHOLIC LIVER DISEASE & FATTY LIVER ASSOCIATED WITH ACUTE GASTROENTERITIS

A 49 years old male patient was admitted in Gastroenterology department of a tertiary care hospital with chief complaints of:

- ✓ Nausea.
- ✓ Vomiting.
- ✓ Pain in abdomen.
- ✓ Blood in the stool.
- ✓ Fever.
- ✓ Abdominal distension
- ✓ Shortness of breath
- ✓ Pedal oedema
- ✓ Ascites

H_X OF PRESENT ILLNESS:

✓ Patient was asymptomatic 2days back, develop Nausea, Vomiting, Abdominal distention, Ascites and loose motions.

PM_X WITH ALLERGIC STATUS:

✓ K/C/O:- Alcoholic liver disease with Fatty Liver

FAMILY HISTORY:

- ✓ Mother-Arthritis
- ✓ Father- Hypertension, Type-2DM.

PHYSICAL EXAMINATION:

- ✓ Temp:-Normal
- ✓ RR:-22/mint
- ✓ PR:-82b/mint
- ✓ BP:-120/80mmHg

DISCUSSION

This is a rare case. The usual cause is obstruction of inferior vena cava (IVC), Atresia of hepatic veins. Two-third of cases of obstruction are due to membranes or webs in IVC and most of the remaining are due to thrombosis in the IVC or hepatic veins¹¹. Lent(1899) his first pathological description of 'obliterative endophlebitis of hepatic veins'. The BCS refers to the clinical picture that occurs when there is obstruction to the hepatic venous outflow. The classic acute presentation is with the triad of ascites, hepatomegaly and abdominal pain¹².

BCS can present as fulminant, acute and chronic. Fulminant is characterized by acute deterioration in hepatic function and encephalopathy. Acute non-fulminant shows significant liver damage and lab abnormalities vary widely. About 25-30% of BCS present acutely¹³.

This patient presented with acute deterioration in liver function and diffuse pain abdomen and ascites. The liver enzymes stabilized on conservative management. There was feature of encephalopathy and bleeding tendency during hospital stay. However, ascites increased and became more tense and painful with prominent dilated veins over chest and abdomen.

CASE REPORT OF BUDD CHAIRI SYNDROME(SOAP FORMAT)

SUBJECTIVE:

A 49yrs old male patient was admitted in the Gastroenterology department of a tertiary care hospital with chief complaints of Abdominal pain, Ascites, Nausea, Vomiting, Fever & blood in stool, Shortness of Breath(SOB), Pedal oedema.

OBJECTIVE:

Laboratory investigation revealed

- ✓ Hb- 10gm/dl,
- \checkmark WBC-7800/mm3,
- ✓ Platelet count-370000/mm3,
- ✓ PCV-36%,
- ✓ Peripheral blood film was unremarkable.
- ✓ SGPT-56U/L(Normal <50U/L)
- ✓ SGOT 50U/L(Normal<45U/L)
- ✓ Serum bilirubin -2.3mg/dl,
- ✓ Prothrombin time was prolonged(patient 21 second, control 12 second)
- ✓ Serum albumin 2.8gm/dl .
- ✓ Ascitic fluid was transudative and negative for malignant cell.
- ✓ APTT 33 second (Normal 26-36second)
- ✓ D-dimers 763 ng/ml (Normal <500ng/ml).
- ✓ Anti-phospholipid Ab(IgGand IgM) were negative.
- ✓ Chest Xray was normal and transthoracic echocardiography revealed thrombus in the right atrium and mild pericardial effusion but no evidence of constrictive pericarditis.

- ✓ Ultrasonogram of whole abdomen showed marked Hepatomegaly with enlargement of the caudate lobe of the liver and ascites.
- ✓ Doppler Ultrasonogram showed dilated inferior venacava with partial occlusion by thrombus, moderate portal hypertension, no evidence of intrahepatic venous obstruction. MRI of abdomen showed total occlusion in proximal inferior venacava with possible intraluminal thrombus in proximal Inferior Venacava (IVC), hepatomegaly, and ascites
- ✓ Upper GIT endoscopy showed grade 1 esophageal varises. Venography revealed right heart catheter could not be passed beyond the level of hepatic vein, complete obstruction in inferior venacava just 1 cm below the diaphragm. Superior venogram showed few millimeter of IVC. There was no indentation of caudate lobe.
- ✓ About 1 year back he was diagnosed as a case of cirrhosis of liver, but now finally after doing venography he is diagnosed as a case of "Budd Chiari Syndrome" due to membranous obstruction of the Inferior Venacava (IVC) with Cirrhosis of Liver.






Figure 2: Dilated IVC, partial occlusion with Thrombus

Figure 3:IVC is total cut just after diaphragm

ASSESSMENT:

❖ A: From the above data the patient was diagnosed with Acute Gastroenteritis ,Hepatic Encephalopathy, Alcoholic Liver Disease, Fatty Liver & Budd chairi syndrome

- I. Problem 1: Nausea & Vomiting.
- II. Problem 2: Blood in the stool.
- III. Problem 3: Fever.
- IV. Problem 4: Burning sensation in Epigastric region.
- V. Problem 5:Budd Chairi syndrome
- VI. Problem 6:Alcoholic Liver Disease
- VII. Problem 7:Fatty Liver
- VIII. Problem 8:Hepatic encephalopathy

PROBLEM 1:-NAUSEA AND VOMITING:

- ✓ Anti-emetic therapy has been started i.e., Zofer, it should be continued.
- ✓ Add Zofer(Ondansetron)4mg IV TID.
- ✓ Management of the diet is a first priority for the treatment of Diarrhoea
- ✓ Rehydration & maintenance of water & electrolytes are the primary treatment measures until the diarrheal episode ends.
- ✓ Advise the patient to maintain Hygienic conditions.
- ✓ Advising patients to increase fluid intake

PROBLEM 2: BLOOD IN STOOL:

- ✓ This is due to Enterotoxin induced inflammatory Gastroenteritis.
- ✓ Sporolac 2Tablets and Inj. Metronidazole 100ml IV TID is suggested by the physician.

PROBLEM 3: FEVER

- \checkmark Temperature is to be monitored q 4th hour,.
- ✓ So, Ibuprofen & Paracetamol can be administered(if Fever persists).

PROBLEM 4: BURNING SENSATION IN THE EPIGASTRIC REGION:

✓ Syrup Sucralfate 10ml PO TID is administered and it is monitered carefully as it Adverse effects are many as it may cause Diarrhoea, Nausea, Constipation and Headache.

PROBLEM:5 BUDD CHAIRI SYNDROME:

✓ Formation of blood clot within the hepatic veins can lead to Budd chairi Syndrome.




Figure 4: Photomicrograph showing histopathologic features of Budd Chairi Syndrome with centrizonal congestion, perivenular fibrosis.

Figure 5: Photomicrograph showing centrizonal congestion and mild degeneration.

TREATMENT OF BCS:-

- ✓ **Anticoagulant therapy** If the blockage is caused by a clot, anticoagulant drugs such as warfarin can help in preventing the clots from recurring. The patient should be monitored regularly to maintain the anticoagulant effect within the acceptable range.
- ✓ **Percutaneous transluminal angioplasty** can help widen the veins narrowed by clots. This procedure involves placing a stent to keep the vein open.
- ✓ **Liver transplant** is another life-saving option especially for people with severe liver decompensation and failure.
- ✓ **Transjugular intrahepatic portal-systemic shunting (TIPS)** can create an alternate route for blood flow thereby bypassing the liver. This reduces the pressure on the hepatic portal vein. This procedure is necessary if the patient presents with portal hypertension.




Figure:6(A) Invasive portography after left-sided Transjugular intrahepatic portal-systemic shunting (TIPS) placement demonstrating patent TIPS perfusion. (B, C) Invasive TIPS-control demonstrating cavernous transformed portal occlusion and restored hepatopetal flow after TIPS elongation: (1) main portal vein; (2) left portal vein; (3) left hepatic vein. TIPS = transjugular portosystemic shunt.

PROBLEM 6:-ALCOHOLIC LIVER DISEASE(ALD):

- ✓ Alcoholic Liver Disease(ALD) is a heterogenous disease & caused by alcoholism and can be divided into 3types:-
- ✓ Hepatic steatosis, Alcoholic hepatitis & Cirrhosis.

Pharmacists intervention:-

✓ All the patients with alcohol related liver disease should abstain from alcohol.(Stop drinking alcohol)

Preventing relapses:-

- ✓ Once the patient stopped drinking alcohol, they need further treatment to help ensure that they don't start drinking again.
- ✓ The first treatment usually offered is psychological therapy.
- ✓ If the psychological therapy alone is not effective, the patient may also need medications to help abstain from alcohol
- ✓ The medications include:

- ✓ Acamprosate
- ✓ Naltrexone
- ✓ Disulfiram

DIET AND NUTRITION:-

✓ Malnutrition is common in people with ARLD(Alcohol- Related Liver Disease), so it is important to take a balanced diet.

PROBLEM 7:-FATTY LIVER:

- ✓ Fatty liver disease consists of Alcoholic liver disease(ALD), and non-alcoholic liver disease(NAFLD).
- ✓ Symptoms:-Malaise, Fatigue, Snores, Disturbed sleep, Chronic pain disorders.
- ✓ Physical examination:-Abdominal obesity, Enlarged liver, RUQ(Right Upper Quadrant) tenderness on palpitations

Pharmacists Interventions:-

- ✓ FATTY LIVER may resolve with weight loss.
- ✓ Diet and exercise improve insulin sensitivity, increase oxidative capacity
- ✓ Modify underlying metabolic risk factors i.e., Diet and Exercise

PROBLEM 8:-HEPATIC ENCEPHALOPATHY

- ✓ For those with severe disease i.e.,hepatic encephalopathy and no contraindications to their use steroids should be considered
- ✓ Liver transplantation remains an option for selected patients with end stage liver disease due to alcohol

PLAN:

✓ Tab.Sporolac(Lactic acid bacillus)2tabs PO TID.

- ✓ Inj.Zofer(Ondansetron)4mg IV TID.
- ✓ Tab.Parasafe(Paracetamol)500mg PO TID.
- ✓ Inj.Metrogyl(Metronidazole)100ml IV TID.
- ✓ Syp.Sucral(Sucralfate)10ml PO TID.
- ✓ IVF 30RL(Ringer Lactate)@100ml/hr
- ✓ IVF 10NS(Normal saline)@100ml/hr
- ✓ Tab Lasix 40mg PO BD.
- ✓ Tab Fruselac(Spironolactone+furosemide) 20mg PO BD
- ✓ Tab.Bilefix(Ursodeoxycholic acid)300mg PO BD

REFERENCES

- 1. Valla DC. Vascular disorders of the liver. Acta Gastroenterol Belg. 2003;66:294–297.
- 2. Budd G. On diseases of the liver. Philadelphia: Lea and Blanchard; 1846.
- 3. Budd G. On diseases of the liver. Philadelphia: Blanchard and Lea; 1857.
- 4. Okuda K, Kage M, Shrestha SM. Proposal of a new nomenclature for Budd-Chiari syndrome: hepatic vein thrombosis versus thrombosis of the inferior vena cava at its hepatic portion. Hepatology. 1998;28:1191–1198. 5. Valla DC. The diagnosis and management of the Budd-Chiari syndrome: consensus and controversies. Hepatology. 2003;38:793–803
- 6. Janssen HL, Garcia-Pagan JC, Elias E, Mentha G, Hadengue A, Valla DC. Budd-Chiari syndrome: a review by an expert panel. J Hepatol. 2003;38:364–371.
- 7. Shrestha SM. Liver cirrhosis and hepatocellular carcinoma in hepatic vena cava disease, a liver disease caused by obstruction of inferior vena cava. Hepatol Int. 2009;3:392–402.
- 8. Okuda K. Membranous obstruction of the inferior vena cava (obliterative hepatocavopathy, Okuda) J Gastroenterol Hepatol. 2001;16:1179–1183.
- 9. DeLeve LD, Valla DC, Garcia-Tsao G. Vascular disorders of the liver. Hepatology. 2009;49:1729-1764
- 10. Valla DC. Hepatic venous outflow tract obstruction etiopathogenesis: Asia versus the West. J Gastroenterol Hepatol. 2004;19:S204–S211.
- 11.Dc B. K., De K. K. Sen S., Biswas P. K, Das T. K., Das S., Hazra B. Etiology based prevalence of BCS in eastern India. J Assoc. Physicians India. 48:800-803, 2000.
- 12. Datta D. V., Saha S., Singh S. A., Gupta B. B., Aikat B. K., Chhuttani P. N. Clinical spectrum of BuddChiari syndrome in Chandigrah with particular reference to obstruction of intrahepatic portion of inferior vena cava. Indian J Med Res. 60:385-402, 1972.
- 13. Arora A., Sharma M. P., Buch P., Mathur M. Paroxysmal nocturnal hemoglobinuria with hepatic vein thrombosis presenting as hepatic encephalopathy. Indian J Gastroenterol. 9:91-92, 1990.
- 14. Acute hepatic dysfunction with abdominal paid and ascites Aamer Agha; Norman Susman et al. Grand rounds in Gastroenterology from Baylor College of Medicine, Huston, Texas).
- 15. Akiyoshi H, Terada T. Centrilobular and perisinusoidal fibrosis in experimental congestive liver in the rat. J Hepatol. 1999;30:433–439.

- 16. Witte CL, Witte MH, Dumont AE. Lymph imbalance in the genesis and perpetuation of the ascites syndrome in hepatic cirrhosis. Gastroenterology. 1980;78:1059–1068.
- 17. Parker RG. Occlusion of the hepatic veins in man. Medicine (Baltimore) 1959;38:369-402.
- 18. Gonzalez-Flecha B, Reides C, Cutrin JC, Llesuy SF, Boveris A. Oxidative stress produced by suprahepatic occlusion and reperfusion. Hepatology. 1993;18:881–889.

